Targeted Disease(s):
Lung Cancer
Purpose of Study:
This study is to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 in Patients With Advanced Solid Tumors
Study Dates:
May 25, 2022 - October 6, 2027
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Medilink Therapeutics
Contact:
Sasha Stann
617-240-8494
sasha@medilinkthera.com
ClinicalTrails.gov Identifier:
NCT05434234
